Antibe Therapeutics Inc. (OTCMKTS:ATBPF) Short Interest Update

Antibe Therapeutics Inc. (OTCMKTS:ATBPF) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totalling 65,100 shares, a growth of 1,934.4% from the March 31st total of 3,200 shares. Based on an average daily volume of 92,600 shares, the short-interest ratio is presently 0.7 days.

Analyst Upgrades and Downgrades

Separately, Brookline Capital Management lowered shares of Antibe Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, March 4th.

Antibe Therapeutics Price Performance

OTCMKTS:ATBPF opened at $0.22 on Friday. Antibe Therapeutics has a one year low of $0.11 and a one year high of $0.89. The company’s 50-day simple moving average is $0.37 and its 200 day simple moving average is $0.53. The firm has a market capitalization of $11.42 million, a P/E ratio of -0.86 and a beta of 0.51.

Antibe Therapeutics (OTCMKTS:ATBPF) last posted its quarterly earnings data on Wednesday, February 14th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.03. On average, equities research analysts expect that Antibe Therapeutics will post -0.31 earnings per share for the current fiscal year.

Antibe Therapeutics Company Profile

Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs).